View how the momentum in Alzheimer's disease research is growing.
Philanthropy is propelling the Alzheimer's Association research strategy for progress in four key outcome areas.
Together we are accelerating advances in biochemistry, genetics, immunology and more by funding best-in-field investigations worldwide. We are also equipping scientists around the globe to share "big data" and analyze it for patterns and correlations that help shed light on the onset and progression of Alzheimer's disease.
Together we are helping ensure physicians and researchers have the clinical tools they need to recognize Alzheimer's early and to differentiate it from normal aging and other dementias — enabling more timely interventions and more effective disease monitoring. This includes a study of the impact that early detection of Alzheimer's may have on major medical outcomes, such as hospital admissions and emergency room visits.
Together we are funding clinical trials diseasetargeting a variety of disease pathways and stages, with a focus on drugs already approved for other conditions to expedite development. We are also exploring the synergistic benefit of taking approved medications in combination; "drug cocktails" have proved effective for treating cancer, heart disease and HIV.
Together we are advancing clinical trials of drugs and lifestyle interventions that may prevent cognitive impairment and dementia in individuals at increased risk for Alzheimer's. We are also funding studies that may lead to the development of Alzheimer's risk profiles in the way the Framingham study did for heart disease.